within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP05_Simeprevir;

model Simeprevir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.44,
    Cl = 1.0555555555555555e-05,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.209,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007833333333333333,
    Tlag = 19.8,
    Vdp = 0.075,
    k12 = 3.638888888888889e-05,
    k21 = 3.638888888888889e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Simeprevir</td></tr><tr><td>ATC code:</td><td>J05AP05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>209</td><td>L</td></tr>
    <tr><td>clearance:</td><td>38</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Simeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor that was used in combination with other antiviral agents for the treatment of chronic hepatitis C infection in adults. While it was approved by the FDA in 2013, its usage has largely been phased out in favor of newer direct-acting antivirals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Valade, E, et al., &amp; Ackaert, O (2018). Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. <i>The AAPS journal</i> 21(1) 1–None. DOI:<a href=\"https://doi.org/10.1208/s12248-018-0272-z\">10.1208/s12248-018-0272-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30377854/\">https://pubmed.ncbi.nlm.nih.gov/30377854</a></p></li><li><p>Valade, E, et al., &amp; Ackaert, O (2018). Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach. <i>The AAPS journal</i> 20(6) 111–None. DOI:<a href=\"https://doi.org/10.1208/s12248-018-0271-0\">10.1208/s12248-018-0271-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30350297/\">https://pubmed.ncbi.nlm.nih.gov/30350297</a></p></li><li><p>Snoeys, J, et al., &amp; Ouwerkerk-Mahadevan, S (2017). Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. <i>Clinical pharmacokinetics</i> 56(7) 781–792. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0476-2\">10.1007/s40262-016-0476-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27896690/\">https://pubmed.ncbi.nlm.nih.gov/27896690</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AP05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Simeprevir;
